公开(公告)号：US10272052B2

公开(公告)日：2019-04-30

申请号：US15905748

申请日：2018-02-26

Applicant: Umesh Kumar Jinwal ,  Vetriselvan Manavalan

Inventor： Umesh Kumar Jinwal ,  Vetriselvan Manavalan

IPC: A61K9/00 ,  A61P25/28 ,  A61K31/055

Abstract: Disclosed herein are compositions and methods for treating tauopathies such as Alzheimer's disease (AD). Also provided herein are methods of reducing or disrupting tau aggregation in a subject, and methods of reducing tau protein in a subject. The methods may include administering to the subject a therapeutic amount of hexachlorophene, or a pharmaceutically acceptable salt thereof. Further provided herein are pharmaceutical compositions comprising hexachlorophene, or a pharmaceutically acceptable salt thereof, for the treatment of a tauopathy in a subject.

公开(公告)号：US20190298663A1

公开(公告)日：2019-10-03

申请号：US16293535

申请日：2019-03-05

Applicant: Umesh Kumar Jinwal ,  Vetriselvan Manavalan

Inventor： Umesh Kumar Jinwal ,  Vetriselvan Manavalan

IPC: A61K31/055 ,  A61P25/28 ,  A61K9/00

Abstract: Disclosed herein are compositions and methods for treating tauopathies such as Alzheimer's disease (AD). Also provided herein are methods of reducing or disrupting tau aggregation in a subject, and methods of reducing tau protein in a subject. The methods may include administering to the subject a therapeutic amount of hexachlorophene, or a pharmaceutically acceptable salt thereof. Further provided herein are pharmaceutical compositions comprising hexachlorophene, or a pharmaceutically acceptable salt thereof, for the treatment of a tauopathy in a subject.

公开(公告)号：US20180250241A1

公开(公告)日：2018-09-06

申请号：US15905748

申请日：2018-02-26

Applicant: Umesh Kumar Jinwal ,  Vetriselvan Manavalan

Inventor： Umesh Kumar Jinwal ,  Vetriselvan Manavalan

IPC: A61K31/055 ,  A61K9/00 ,  A61P25/28

CPC classification number: A61K31/055 ,  A61K9/0019 ,  A61P25/28

Abstract: Disclosed herein are compositions and methods for treating tauopathies such as Alzheimer's disease (AD). Also provided herein are methods of reducing or disrupting tau aggregation in a subject, and methods of reducing tau protein in a subject. The methods may include administering to the subject a therapeutic amount of hexachlorophene, or a pharmaceutically acceptable salt thereof. Further provided herein are pharmaceutical compositions comprising hexachlorophene, or a pharmaceutically acceptable salt thereof, for the treatment of a tauopathy in a subject.